26. January 2016

Zedira supports Gordon Research Conference on "Transglutaminases in Human Disease Processes"



Zedira supports Gordon Research Conference on
“Transglutaminases in Human Disease Processes: Understanding the Varied Pathological Roles of a Multifunctional Enzyme Family”

Zedira is very proud to support for the 4th time the Gordon Research Conference dedicated to Transglutaminase. The conference will be held from July 10th until July 15th, 2016 at PGA Catalunya Business and Convention Centre in Girona, Spain.

“The 4th Gordon Research Conference on "Transglutaminases in Human Disease Processes" will delve into many disease areas to try and establish where Transglutaminases are central to the disease process so we can better understand the interaction of function with the pathogenic roles being ascribed.” (Source GRC)

Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
    All products

News  

  • Zedira supports Gordon Research Conference
    Read more All news
  • imagePress release: Zedira announces ISO 9001:2015 certification
    Read more All news
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
    Read more All news
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
    Read more All news
  • imagePreview: Catalogue Editorial 2019
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
    Read more All news
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
    Read more All news
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
    Read more All news
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    Read more All news
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
    Read more All news
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
    Read more All news
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
    Read more All news
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
    Read more All news
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
    Read more All news
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
    Read more All news
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation
    Read more All news

Blog  

Events  

  • Canceled and rescheduled: Gordon Research Conference

    14.06.2020 - 19.06.2020
    Mount Snow, USA

    All events
  • Canceled and rescheduled: Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland

    All events
  • 19th International Celiac Disease Symposium

    30.09.2021 - 03.10.2021
    Sorrento, Italy

    All events